Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$22.96.

  • Viridian Therapeutics, Inc.\DE's EPS (Basic) rose 6107.81% to -$22.96 in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.13, marking a year-over-year increase of 5031.34%. This contributed to the annual value of -$3.98 for FY2024, which is 2513.87% up from last year.
  • Viridian Therapeutics, Inc.\DE's EPS (Basic) amounted to -$22.96 in Q3 2025, which was up 6107.81% from -$66.99 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year EPS (Basic) high stood at -$0.86 for Q3 2022, and its period low was -$178.15 during Q4 2022.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's EPS (Basic) averaged around -$26.02, with its median value being -$2.21 (2021).
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's EPS (Basic) crashed by 723544.72% in 2022 and then soared by 9916.14% in 2023.
  • Viridian Therapeutics, Inc.\DE's EPS (Basic) (Quarter) stood at -$2.43 in 2021, then plummeted by 7235.45% to -$178.15 in 2022, then surged by 99.16% to -$1.49 in 2023, then grew by 21.33% to -$1.18 in 2024, then crashed by 1853.62% to -$22.96 in 2025.
  • Its EPS (Basic) stands at -$22.96 for Q3 2025, versus -$66.99 for Q2 2025 and -$57.94 for Q1 2025.